<DOC>
	<DOC>NCT01223768</DOC>
	<brief_summary>To assess the clinical efficacy of ALC in the treatment of severe hepatic encephalopathy (grade 3 of the West Haven grading scale), we performed a randomised, double blind placebo-controlled study administering ALC to cirrhotic patients, evaluating the effects on ammonia levels and performance in cognitive functions.</brief_summary>
	<brief_title>Acetyl-L-Carnitine In Severe Hepatic Encephalopathy</brief_title>
	<detailed_description />
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Acetylcarnitine</mesh_term>
	<criteria>patients with severe hepatic encephalopathy (grade 3 of the West Haven grading scale) with hepatic cirrhosis Patients with a history of recent alcohol abuse, patients using psychotropic drugs (e.g., antipsychotics, interferon, benzodiazepines, antiepileptics, sedatives and antidepressants) Other exclusion criteria were the following: major complications of portal hypertension, such as gastrointestinal blood loss, hepatorenal syndrome or bacterial peritonitis; acute superimposed liver injury;patients with metabolic disorders such as diabetes mellitus, unbalanced heart failure and/or respiratory failure or endstage renal disease; any additional precipitating factors such as high protein intake (additional highprotein meals), constipation; illiteracy.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2000</verification_date>
</DOC>